Mantle-cell lymphoma - PubMed

Affiliations

• PMID: 10319380

Review

Mantle-cell lymphoma

E Campo et al. Semin Hematol. 1999 Apr.

Abstract

Mantle-cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells characterized by a nodular or diffuse proliferation of atypical lymphoid cells with a monoclonal B-cell phenotype and coexpression of CD5. Two cytologic variants have been identified, typical and blastic. Typical cases show a proliferation of small to intermediately sized lymphoid cells with irregular nuclei and scarce cytoplasm. Blastic variants include a spectrum of intermediate to large cells with round or irregular nuclei and finely dispersed chromatin. These cases have a higher proliferative activity and a more aggressive clinical evolution. MCL is genetically characterized by 11q13 translocations and bcl-1 rearrangement. This alteration leads to a constant overexpression of cyclin D1, which plays an important pathogenetic role, probably deregulating cell-cycle control by overcoming the suppressor effect of retinoblastoma protein (Rb) and p27Kip1. Detection of cyclin D1 may be used as a highly specific marker of MCL because it is expressed in virtually all of these tumors, but in only a few reported cases of aggressive variants of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and a small percentage of cases of multiple myeloma. Aggressive variants have additional genetic alterations, including inactivation of p53 and p16INK4a tumor-suppressor genes. Clinically, MCL presents in elderly males with advanced disease and frequent extranodal involvement, particularly with involvement of bone marrow, gastrointestinal tract, and spleen. The clinical evolution is relatively aggressive, with poor response to conventional therapeutic regimens and a median survival duration of 3 to 4 years. Further studies are needed to define better new therapeutic strategies for the management of these patients.

Similar articles

• BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32).

  De Angeli C, Gandini D, Cuneo A, Moretti S, Bigoni R, Roberti MG, Bardi A, Castoldi GL, del Senno L. De Angeli C, et al. Haematologica. 2000 Sep;85(9):913-21. Haematologica. 2000. PMID: 10980628

• p27(Kip1) immunostaining for the differential diagnosis of small b-cell neoplasms in trephine bone marrow biopsies.

  Kremer M, Dirnhofer S, Nickl A, Hoefler H, Quintanilla-Martínez L, Fend F. Kremer M, et al. Mod Pathol. 2001 Oct;14(10):1022-9. doi: 10.1038/modpathol.3880429. Mod Pathol. 2001. PMID: 11598173

• Molecular control of the cell cycle in cancer: biological and clinical aspects.

  Møller MB. Møller MB. Dan Med Bull. 2003 May;50(2):118-38. Dan Med Bull. 2003. PMID: 12812137 Review.

• Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma.

  Viswanatha DS, Foucar K, Berry BR, Gascoyne RD, Evans HL, Leith CP. Viswanatha DS, et al. Mod Pathol. 2000 Jul;13(7):825-33. doi: 10.1038/modpathol.3880144. Mod Pathol. 2000. PMID: 10912944

• [Pathologic diagnosis of mantle cell lymphoma based on histologic, cytologic, immunohistologic and genetic characteristics].

  László T, Csernus B, Krenács L, Kelényi G, Matolcsy A. László T, et al. Orv Hetil. 1999 Dec 26;140(52):2907-12. Orv Hetil. 1999. PMID: 10659642 Review. Hungarian.

Cited by

• [DNA-chips in the diagnosis of hematological malignancies].

  Feuring-Buske M, Hartmann EM, Ott G, Reuter H, Buske C, Rosenwald A. Feuring-Buske M, et al. Internist (Berl). 2006 Jan;47(1):39-46. doi: 10.1007/s00108-005-1526-2. Internist (Berl). 2006. PMID: 16247632 Review. German.

• Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.

  Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D, Devos S, Cheson BD, Damon LE, Said J. Hsi ED, et al. Leuk Lymphoma. 2008 Nov;49(11):2081-90. doi: 10.1080/10428190802419640. Leuk Lymphoma. 2008. PMID: 19021050 Free PMC article. Clinical Trial.

• The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma.

  Zhang Y, Molavi O, Su M, Lai R. Zhang Y, et al. BMC Cancer. 2014 Oct 29;14:791. doi: 10.1186/1471-2407-14-791. BMC Cancer. 2014. PMID: 25355139 Free PMC article.

• Multiple lymphomatous polyposis with diffuse involvement of the gastrointestinal tract. Case report.

  Cestaro G, De Rosa M, Vitiello C, Galloro G, Gentile M. Cestaro G, et al. G Chir. 2013 May-Jun;34(5-6):173-5. doi: 10.11138/gchir/2013.34.5.173. G Chir. 2013. PMID: 23837958 Free PMC article.

• Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study.

  Todorovic M, Balint B, Andjelic B, Stanisavljevic D, Kurtovic NK, Radisavljevic Z, Mihaljevic B. Todorovic M, et al. Med Oncol. 2012 Sep;29(3):2212-9. doi: 10.1007/s12032-011-0136-1. Epub 2011 Dec 15. Med Oncol. 2012. PMID: 22170090

Publication types

MeSH terms

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal